Generational trends in reproductive factors among women in the US: implications for breast cancer incidence [0.03%]
美国女性生育因素的代际变化趋势及其对乳腺癌发病率的影响
Lin Yang,Adetunji T Toriola
Lin Yang
Background: Reproductive factors are key breast cancer risk factors, yet contemporary generational patterns remain unclear. We aimed to evaluate trends in reproductive factors among US women born between 1910 and 2000. ...
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer [0.03%]
PI3K/AKT/mTOR通路抑制剂阿培利塞和everolimus序贯用于激素受体阳性转移性乳腺癌患者
Sherry Shen,Jimmitti Teysir,Anton Safonov et al.
Sherry Shen et al.
Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ [0.03%]
Nano-Luciferase-CD63标记揭示了导管原位癌小鼠胰管内模型中细胞外囊泡的动力学规律
Cole Hladik,Sugantha Priya Elayapillai,Samrita Dogra et al.
Cole Hladik et al.
Background: Ductal carcinoma in situ (DCIS) is a non-invasive precursor to breast cancer that increases lifetime risk for invasive disease and, in rare cases, causes distant metastases without local recurrence. Tumor-deri...
Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer [0.03%]
靶向糖皮质激素受体可增强三阴性乳腺癌的免疫治疗反应
Lei Yang,Zhenzhou Chen,Yajun Chen et al.
Lei Yang et al.
Background: Immune checkpoint blockade (ICB) therapies for triple negative breast cancer (TNBC) have yielded limited clinical benefits, which may be attributed to the immunosuppressive tumor immune microenvironment (TIME)...
One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer [0.03%]
量体裁衣：基于患者报告结果的以数据为导向的洞见以定制乳腺癌支持治疗措施
Eva Boomstra,Kelly M de Ligt,Renaud Tissier et al.
Eva Boomstra et al.
The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy [0.03%]
免疫微环境对保乳术治疗导管原位癌局部控制影响的研究
Fei-Fei Xu,Sai-Fang Zheng,Zi-Yu Shao et al.
Fei-Fei Xu et al.
Toxicity profiles of proton and photon radiotherapy in postoperative breast cancer: a 10-year real-world cohort study [0.03%]
术后乳腺癌质子和光子放射治疗的毒性分析：一项为期10年的队列研究
Chi-Chang Yu,Ching-Chuan Hsieh,Yi-Ting Huang et al.
Chi-Chang Yu et al.
HSP90AA1-VDAC1 interaction contributes to breast cancer progression and doxorubicin resistance through PI3K/AKT signaling [0.03%]
HSP90AA1-VDAC1相互作用通过PI3K/AKT信号促进乳腺癌进展和多柔比星抗性
Yutong Fang,Cuiping Guo,Fengtao Zheng et al.
Yutong Fang et al.
High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune responses [0.03%]
循环中高水平的miR-19a-3p与转移性HER2+乳腺癌患者的良好预后和抗肿瘤免疫反应相关
Evan N Cohen,Hui Gao,Sanda Tin et al.
Evan N Cohen et al.
Background: Trastuzumab, combined with chemotherapy, is the current standard treatment for both metastatic and early-stage HER2-positive (HER2 +) breast cancer. One of the mechanisms of action of trastuzumab is antibody-d...
Diagnostic accuracy of FDG-PET-CT to predict axillary lymph node response after neo-adjuvant chemotherapy in lymph node-positive breast cancer patients [0.03%]
氟脱氧葡萄糖正电子发射断层扫描-X线计算机体层摄影用于预测新辅助化疗后阳性淋巴结乳腺癌患者腋窝淋巴结反应的诊断准确性
Kiran Kasper Rajan,Joni J Nijveldt,Jasper H G Helthuis et al.
Kiran Kasper Rajan et al.